Higher Dose UFH: Centre wide policy of administering 100 U/kg bolus of intravenous UFH for elective PCI procedures
Lower Dose UFH: Centre wide policy of administering 70 U/kg bolus of intravenous UFH for elective PCI procedures
Study summary
HD PCI is a multicenter, randomized, registry-based, cluster crossover design trial of higher dose versus lower dose heparin in patients undergoing elective percutaneous coronary intervention (PCI).
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
\- Patients undergoing elective PCI
Exclusion Criteria:
* Age \<18 years
* Planned chronic total occlusion PCI
* Non-resident precluding follow up through local registries
Hospital (Cluster) Eligibility Criteria
Hospitals will be eligible to participate if they meet the following criteria:
* Submit PCI procedure data to a compatible registry that is able to provide data for the trial
* Site agrees to manage patients as per the higher or lower dose heparin policy in place during the given crossover period
Primary outcome measure(s)
Number of Participants with any of the following: death, myocardial infarction or target vessel revascularization — up to 30 days after PCI
Trial sites (1)
Facility
City
Region
Status
Hamilton Health Sciences, General Hospital
Hamilton
Ontario
Recruiting
More Population Health Research Institute trials in Canada
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.